ESTA

Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
Wednesday, February 28, 2024
General Health, Surgery, Medical Devices, Health, Health Technology, ESTA, Total, Investment, FDA, Expander, Video game

Fourth quarter net loss from operations of $22.1 million compared to a net loss of $13.2 million in the year-ago period.

Key Points: 
  • Fourth quarter net loss from operations of $22.1 million compared to a net loss of $13.2 million in the year-ago period.
  • Total operating expenses for the fourth quarter were $42.7 million, an increase of $1.4 million compared to $41.3 million in the fourth quarter of 2022.
  • SG&A expenses for the fourth quarter increased approximately $2.1 million to $36.9 million compared to $34.8 million in the fourth quarter of 2022.
  • Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results.

Establishment Labs Announces Participation in Two Upcoming Investment Conferences

Retrieved on: 
Friday, February 23, 2024
Health, Medical Devices, Consumer, Women, Surgery, Other Health, Clinical Trials, ESTA, Conference

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
  • Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day.
  • Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak to conference attendees on Thursday, February 29, 2024 at 2:30–3:10 p.m.
  • Live webcasts of the presentations will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/ .

Establishment Labs Announces Amended Credit Facility with Oaktree

Retrieved on: 
Thursday, February 22, 2024
Medical Devices, Health, Consumer, Surgery, Women, Health Technology, ESTA, FDA, Oaktree Capital Management, Form, Interest, Motiva, Security (finance), Tranche

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
  • The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged.
  • “This amended facility provides access to additional capital, should we need it, to ensure our successful launch of Motiva Implants in the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • We look forward to continuing our long-term relationship with Establishment Labs and are excited for what lies ahead.”
    A Form 8-K outlining the full terms of the credit facility will be filed with the Securities and Exchange Commission.

Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28

Retrieved on: 
Wednesday, February 14, 2024
Health Technology, Health, Surgery, Medical Devices, International, ESTA

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
  • To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13744589.
  • The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com .

Establishment Labs Announces Commercial Launch of Motiva Implants in China

Retrieved on: 
Monday, January 22, 2024
Medical Devices, Health, Consumer, Surgery, Women, Other Health, Woman, Beauty, ESTA, Conference, Labs, NMPA, National Medical Products Administration, Growth

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China.
  • “China is the second largest market globally, but has the opportunity to be much larger,” commented Juan José Chacón-Quirós, Establishment Labs Founder and Chief Executive Officer.
  • “Establishment Labs was founded to make profound changes to our industry, and our growth reflects that.
  • Establishment Labs received National Medical Products Administration (NMPA) approval in China for Motiva® Implants in November 2023.

Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023

Retrieved on: 
Tuesday, January 9, 2024
Surgery, Medical Devices, Other Health, Health, Clinical Trials, Sale, RTW, Exercise, ESTA, Growth, Security (finance)

The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.

Key Points: 
  • The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be in the range of $31.4 million to $31.8 million, in line with the guidance provided on November 7 in the third quarter earnings release.
  • Based on the expected range for fourth quarter preliminary unaudited revenue, Establishment Labs expects full-year 2023 revenue of $165.0 million to $165.4 million.
  • Establishment Labs expects to use net proceeds from the private placement for working capital and other general corporate purposes.

Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

Retrieved on: 
Tuesday, January 2, 2024
Surgery, Medical Devices, Women, Health Technology, Biotechnology, Health, Consumer, General Health, Oncology, Rabbit, MRI, Motiva, ESTA, FDA, Magnet, Mouse, MD, Human, Inflammation, University, Establishment, MD Anderson Cancer Center, Radiation, RFID, Patient, Plastic surgery, Medical imaging

The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery.

Key Points: 
  • The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery.
  • "This Flora device is a new resource in our toolkit for breast cancer reconstruction,” Dr. Clemens noted.
  • The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA.
  • By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment.

Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 28, 2023
Surgery, Medical Devices, Women, Consumer, Health, Webcast, Conference, ESTA

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. Pacific Time.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. Pacific Time.
  • A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/ .
  • An archived version of the webcast will be available on the same website following completion of the event.

Establishment Labs Announces Participation in Two Upcoming Investment Conferences

Retrieved on: 
Friday, November 10, 2023
Retail, Health, Medical Devices, Consumer, Women, Surgery, Other Health, ESTA, Conference, Nightclub

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
  • Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2023 Jefferies London Healthcare Conference held November 14-16, 2023.
  • Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak in person to conference attendees on Tuesday, November 14 at 4:30-4:55 PM GMT.
  • Mr. Denhoy will also participate in the Stephens Annual Investment Conference, being held on November 14-16, 2023.

THE NAMM SHOW WELCOMES PRO AUDIO'S BIGGEST BRANDS IN FULL FORCE WITH PACKED HALLS AND A STACKED SCHEDULE

Retrieved on: 
Tuesday, November 28, 2023
Anaheim Convention Center, EAW, NAMM, Shure, Safety, The, NAMM Show, TEC Awards, Sony, Allen & Heath, ESTA, PMC, FBT, QSC, Dante (networking), Music Tribe, DiGiCo, National Association, Sennheiser, RCF, FOH, Inside Story, AVID, DPA Microphones, Education, Electro-Voice, Blackmagic Design, Music, Cassette tape, Midas, Genelec

CARLSBAD, Calif., Nov. 28, 2023 /PRNewswire/ -- NAMM (The National Association of Music Merchants), the largest global not-for-profit music trade organization, is ready to celebrate its role as the U.S. home of pro audio when the NAMM Show opens its doors in January 2024.

Key Points: 
  • Those and dozens more are set to help make this one of the biggest NAMM shows on record, replete with new technology and countless product demonstrations.
  • Outside the exhibit hall, NAMM members can book into official Dante training by Audinate with sessions taking place on January 25 – January 27.
  • Four special Pro Production seminars, hosted by PLSN and FOH magazines, will fill room 204A on Friday January 26.
  • Of course, no NAMM Show would be complete without an unforgettable fringe festival of awards ceremonies, star-studded performances and pool parties.